|Bid||19.16 x 1000|
|Ask||20.94 x 200|
|Day's range||19.69 - 20.15|
|52-week range||16.28 - 20.15|
|PE ratio (TTM)||17.10|
|Forward dividend & yield||0.42 (2.13%)|
|1y target est||N/A|
A Relative Strength Rating upgrade for Keycorp shows improving technical performance. Will it continue?
With Trump administration's deregulation in vogue, it's "game on" for a bank merger boom, says equity research analyst Dick Bove.
KeyCorp (KEY: NYSE) By Evercore ISI ($18.25, Oct. 19, 2017) We reiterate our Outperform rating on KeyCorp but lower our target price from $21 to $20 on our estimate revision. Expenses and weaker loan growth ...
KeyCorp's (KEY) Q3 earnings are expected to be adversely impacted by a fall in net interest income while a modest increase in fee income and lower costs will likely act as tailwinds.
The firm said it recapitalized Delphi Behavioral Health Group LLC, a provider of addiction and detox treatment programs.
Evercore ISI For third-quarter earnings, we favor KeyCorp and Wells Fargo among regional banks. KeyCorp realized its original $400 million of First Niagara-related cost savings as of June 30 (deal closed July 29, 20016), and expects to realize an incremental $50 million in cost savings over the remainder of 2017 and 2018.
Investors' optimism remained upbeat on rising Treasury yields and steady growth in the U.S. economy.
With an aim to expand healthcare advisory, KeyCorp's (KEY) corporate and investment banking unit, KeyBanc Capital, closes Cain Brothers' buyout.
Jim Cramer spoke with KeyCorp Chairman and CEO Beth Mooney for more on the company's latest earnings report and its prospects.
Jim Cramer says earnings and mergers, not Wednesday's tax announcement, are the real factors pushing the market higher.